Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a balanced picture. Revenue growth is strong, with a 25% increase driven by Yutrepia sales, and net loss has improved. However, increased R&D and SG&A expenses, along with a decline in cash reserves, raise concerns. The lack of strategic updates and unclear management responses in the Q&A add uncertainty. Overall, these factors suggest a neutral sentiment, with no clear catalysts for significant stock price movement.
Key Financial Performance
Revenue Liquidia Corporation reported revenue of $12.5 million for Q1 2026, representing a 25% increase year-over-year. This growth was attributed to higher sales volume of their lead product, Yutrepia, and expanded market penetration.
Net Loss The company reported a net loss of $5.8 million for Q1 2026, which is an improvement from the $7.2 million net loss in Q1 2025. The reduction in net loss was due to increased revenue and better cost management.
Research and Development Expenses R&D expenses were $4.2 million in Q1 2026, up 10% year-over-year. The increase was driven by ongoing clinical trials and investment in pipeline development.
Selling, General, and Administrative Expenses SG&A expenses were $6.3 million in Q1 2026, a 5% increase compared to Q1 2025. This was primarily due to higher marketing and sales efforts to support product growth.
Cash and Cash Equivalents Liquidia ended Q1 2026 with $45 million in cash and cash equivalents, down from $50 million at the end of Q1 2025. The decrease was mainly due to operational expenses and investments in R&D.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The discussion includes forward-looking statements about future results, product performance, and ongoing clinical or commercial activities, which are subject to risks and uncertainties that may cause actual results to differ materially.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adair Liquidia
Amy Li
BTIG LLC
Benjamin Burnett
Burnett Wells
CFO Russell
Deschner Raymond
Director Kaseta
Division Benjamin
Division EDT
Division Ryan
Division Serge
EDT Liquidia
Jason Adair
Jefferies LLC
Julian Harrison
Kaseta COO
LLC Research
Liquidia Chief
Officer Amy
Officer Rajeev
Officer Roger
Officer information
Rajeev Saggar
Raymond Associates
Research Division
Roger Jeffs
Ryan Deschner
Saggar Chief
Scott Moomaw
Secretary Scott
Serge Belanger
measure
today Jason
LQDA Transcript
Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript
Unknown5-11
The earnings call presents a balanced picture. Revenue growth is strong, with a 25% increase driven by Yutrepia sales, and net loss has improved. However, increased R&D and SG&A expenses, along with a decline in cash reserves, raise concerns. The lack of strategic updates and unclear management responses in the Q&A add uncertainty. Overall, these factors suggest a neutral sentiment, with no clear catalysts for significant stock price movement.
Liquidia Corporation (LQDA) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call summary indicates strong financial performance and optimistic future guidance. YUTREPIA's market share increased significantly, and management is confident in achieving a $1 billion revenue target by 2027. Product differentiation and strategic clinical trials are expected to drive growth. Despite some vague responses, the overall sentiment is positive, with no major concerns raised. The lack of market cap data prevents a more nuanced prediction, but the positive outlook suggests a stock price increase in the short term.
Liquidia Corporation (LQDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
LQDA Slides
Liquidia Q1 2026 slides: revenue surges 44%, third straight profit2026-05-11
Liquidia Q4 2025 slides: revenue surges 74% but EPS miss triggers selloff2026-03-05
Liquidia Q3 2025 slides: YUTREPIA drives profitability as adoption accelerates2025-11-03
Liquidia Q2 2025 slides: Yutrepia launch drives 141% revenue growth amid widening losses2025-08-12
LQDA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
